GILEAD SCIENCES, INC. — Director's Dealing 2018

Feb 5, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: GILEAD SCIENCES INC (GILD)
CIK: 0000882095
Period of Report: 2018-02-01

Reporting Person: Alton Gregg H (EVP,Corporate &Medical Affairs)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2018-02-01	Common Stock	M	17250	$40.56	Acquired	62738	Direct
2018-02-01	Common Stock	S	9786	$83.2879	Disposed	52952	Direct
2018-02-01	Common Stock	S	15214	$83.6601	Disposed	37738	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2018-02-01	Non-qualified Stock Option (Right to Buy)	$40.56	M	17250	Disposed	2023-02-01	Common Stock (17250)	Direct
2018-02-01	Non-qualified Stock Option (Right to Buy)	$83.49	A	62910	Acquired	2028-02-01	Common Stock (62910)	Direct

Footnotes

F1: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan.

F2: The options have a four year vesting schedule. 25% of the options will vest on the first anniversary date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.

F3: Sale prices reported for the transactions reported here range from $82.49 to $83.49. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request.

F4: Sale prices reported for the transactions reported here range from $83.49 to $84.04. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request.